727 related articles for article (PubMed ID: 16267020)
1. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
2. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
Fang CX; Yang X; Sreejayan N; Ren J
Exp Neurol; 2007 Jan; 203(1):196-204. PubMed ID: 16962100
[TBL] [Abstract][Full Text] [Related]
3. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
Vanderweele DJ; Rudin CM
Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
[TBL] [Abstract][Full Text] [Related]
5. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
6. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
Woodard J; Sassano A; Hay N; Platanias LC
Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
[TBL] [Abstract][Full Text] [Related]
7. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
Nozawa H; Watanabe T; Nagawa H
Cancer Lett; 2007 Jun; 251(1):105-13. PubMed ID: 17175097
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation.
Nomura M; He Z; Koyama I; Ma WY; Miyamoto K; Dong Z
Mol Carcinog; 2003 Sep; 38(1):25-32. PubMed ID: 12949840
[TBL] [Abstract][Full Text] [Related]
12. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
[TBL] [Abstract][Full Text] [Related]
13. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
Dobashi Y; Suzuki S; Matsubara H; Kimura M; Endo S; Ooi A
Cancer; 2009 Jan; 115(1):107-18. PubMed ID: 19090006
[TBL] [Abstract][Full Text] [Related]
14. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
[TBL] [Abstract][Full Text] [Related]
15. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma.
Brown RE; Zhang PL; Lun M; Zhu S; Pellitteri PK; Riefkohl W; Law A; Wood GC; Kennedy TL
Ann Clin Lab Sci; 2006; 36(3):273-82. PubMed ID: 16951268
[TBL] [Abstract][Full Text] [Related]
16. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
17. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway.
Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB
Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
[TBL] [Abstract][Full Text] [Related]
19. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
